Since MyoVin-1 and PBP are likely to inhibit all members of the class V myosins and the reported opposite roles on MYO5A and MYO5B in CRC, the prospects for therapeutic use of class V myosin inhibitors in treating colon cancer remain unclear. This evidence concerns the gene MYO5A and colonic neoplasm.